Statement of the CEO

Senzime has started the rollout of TetraGraph during 2018. A new important chapter in the company’s history has begun. At the same time, we have just started the journey towards achieving our ambition to become a world leader in patient monitoring.

Following a rigorous development and regulatory period we now begin a new phase where commercial focus and patient needs will be central. Surgeons, anesthetists and healthcare professionals all around the world needs to be able to more easily monitor patients before, during and after surgery. We can offer them solutions for high quality follow-up and monitoring that enables patients to recover faster and more safely.

TetraGraph’s launch was initiated through several distribution and licensing agreements. Now we need a focused and proactive commercial support to our existing partnerships, key- and new markets to increase our sales. This is our priority for 2019.

In 2018, we also gained confidence from new institutional owners who provided capital for our commercialization and growth phase. Senzime has a good starting position and I look forward to leading the company’s continued development.

Uppsala in February 2019, Pia Renaudin, CEO of Senzime AB (publ)